Banco de Sabadell S.A decreased its position in Johnson & Johnson (NYSE:JNJ) by 51.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,001 shares of the company’s stock after selling 15,115 shares during the quarter. Banco de Sabadell S.A’s holdings in Johnson & Johnson were worth $1,839,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Johnson & Johnson by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 38,393,079 shares of the company’s stock valued at $5,589,167,000 after acquiring an additional 1,364,028 shares during the period. Bank of New York Mellon Corp lifted its holdings in Johnson & Johnson by 3.2% in the fourth quarter. Bank of New York Mellon Corp now owns 32,846,195 shares of the company’s stock valued at $4,791,274,000 after acquiring an additional 1,021,877 shares during the period. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter valued at about $4,139,107,000. Massachusetts Financial Services Co. MA lifted its holdings in Johnson & Johnson by 3.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 27,407,188 shares of the company’s stock valued at $3,997,886,000 after acquiring an additional 915,066 shares during the period. Finally, FMR LLC lifted its holdings in Johnson & Johnson by 4.7% in the fourth quarter. FMR LLC now owns 17,945,766 shares of the company’s stock valued at $2,617,750,000 after acquiring an additional 799,194 shares during the period. 68.51% of the stock is currently owned by institutional investors.
Several research firms have recently commented on JNJ. Stifel Nicolaus raised their price objective on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Morgan Stanley raised their price objective on Johnson & Johnson from $160.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Argus reaffirmed a “buy” rating and issued a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Credit Suisse Group reaffirmed a “buy” rating and issued a $161.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Finally, SVB Leerink decreased their price objective on Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $163.47.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.27. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. The firm had revenue of $20.69 billion during the quarter, compared to analysts’ expectations of $19.48 billion. During the same quarter last year, the business posted $2.10 earnings per share. The firm’s revenue was up 3.3% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 7.68 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.75%. The ex-dividend date is Friday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
In other news, Director William D. Perez purchased 500 shares of the business’s stock in a transaction on Friday, March 13th. The stock was acquired at an average price of $127.69 per share, for a total transaction of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is the definition of market timing?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.